Alyeska Investment Group’s Ionis Pharmaceuticals IONS Stock Holding History

Alyeska Investment Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.5M	Sell	473,150 -8,561	-2%	-$676K	0.1%	229
2025 Q4	$38.1M	Buy	481,711 +170,453	+55%	+$12.8M	0.11%	228
2025 Q3	$20.4M	Buy	311,258 +152,250	+96%	+$7.43M	0.06%	282
2025 Q2	$6.28M	Buy	+159,008	New	+$5.2M	0.02%	397
2025 Q1	–	Sell	-150,000	Closed	-$5.24M	–	582
2024 Q4	$5.24M	Sell	150,000 -18,951	-11%	-$708K	0.02%	396
2024 Q3	$6.77M	Buy	+168,951	New	+$7.86M	0.03%	324
2021 Q2	–	Sell	-427,990	Closed	-$19.2M	–	779
2021 Q1	$19.2M	Buy	427,990 +225,513	+111%	+$12.6M	0.25%	126
2020 Q4	$11.4M	Buy	+202,477	New	+$10.1M	0.16%	176

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's IONS Position: Q1 2026 in Review

Alyeska Investment Group reduced its Ionis Pharmaceuticals (IONS) stake by 1.8% in Q1 2026, selling an estimated $676K and leaving 473,150 shares worth $35.5M. The position accounts for 0.1% of the portfolio, ranked #229.

Alyeska Investment Group first reported a position in IONS in Q4 2020 and has held it in 8 quarters since. The position peaked at $38.1M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Alyeska Investment Group held 473,150 shares of Ionis Pharmaceuticals worth $35.5M as of Q1 2026.
Alyeska Investment Group sold 8,561 Ionis Pharmaceuticals shares in Q1 2026, an estimated $676K.
Ionis Pharmaceuticals made up 0.1% of Alyeska Investment Group's portfolio in Q1 2026, its #229 holding.
Alyeska Investment Group first reported a position in Ionis Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
Alyeska Investment Group's Ionis Pharmaceuticals position peaked at $38.1M in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.